| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Helioxanthin's primary target is the hepatitis B virus (HBV), although its exact molecular target is not fully elucidated. It exhibits antiviral activity against HBV and flaviviruses. The compound's mechanism of action is believed to involve inhibition of viral replication, but the specific viral or host proteins it interacts with have not been definitively identified. Its activity against flaviviruses suggests a broad-spectrum antiviral potential. Further research is needed to identify its precise molecular target and to understand its mechanism of action in detail.
|
|---|---|
| ln Vitro |
In vitro, Helioxanthin demonstrates potent antiviral activity against hepatitis B virus (HBV) with an EC50 of 1 μM. It is also active against flaviviruses. The compound's activity is typically measured using cell-based assays, such as HBV replicon assays, where the reduction in viral DNA or antigen levels is quantified. Its analogues have been shown to exhibit significant in vitro antiviral activity, suggesting that the core structure is important for its antiviral properties. These in vitro findings establish Helioxanthin as a potent antiviral agent against HBV and flaviviruses.
|
| ln Vivo |
In vivo activity data for Helioxanthin is limited, as the compound is primarily used as a research tool in in vitro studies. While it has shown potent in vitro antiviral activity, its in vivo efficacy and pharmacokinetic properties have not been extensively characterized in standard product descriptions. The compound could potentially be evaluated in animal models of HBV infection, such as the hydrodynamic injection mouse model or the humanized liver mouse model. However, specific in vivo protocols and results are not detailed in the available literature. Its use remains confined to in vitro research.
|
| Enzyme Assay |
The in vitro assays for Helioxanthin measure its antiviral activity against HBV and flaviviruses. For HBV, the most common assay is the HBV replicon assay. In this assay, human hepatoma cells (e.g., HepG2.2.15) that stably replicate HBV are treated with varying concentrations of Helioxanthin. After incubation, the levels of HBV DNA or the secretion of HBV surface antigen (HBsAg) and e antigen (HBeAg) are measured. The EC50, which is the concentration that inhibits 50% of viral replication or antigen production, is determined from dose-response curves. For flaviviruses, similar cell-based assays using virus-infected cells are employed.
|
| Cell Assay |
In vitro cell-based assays for Helioxanthin are conducted using HBV-replicating cell lines, such as HepG2.2.15 cells. In a typical assay, cells are seeded in multi-well plates and treated with Helioxanthin at various concentrations. After a defined incubation period (e.g., 3-5 days), the culture supernatant is collected to measure the levels of HBsAg and HBeAg by ELISA. Intracellular HBV DNA can also be quantified by real-time PCR. The EC50 is determined from the dose-response curve. For flavivirus studies, cells are infected with the virus and then treated with Helioxanthin. Viral replication is quantified by measuring viral titers or by detecting viral proteins via immunofluorescence.
|
| Animal Protocol |
In vivo animal experiments for Helioxanthin are not extensively described in the available literature. As a research compound with in vitro antiviral activity, it could be evaluated in animal models of HBV infection. For example, the hydrodynamic injection mouse model, where HBV DNA is injected into the tail vein of mice to establish transient infection, could be used. Helioxanthin would be administered orally or by injection, and viral load in the blood and liver would be measured over time. However, specific protocols for Helioxanthin are not detailed. Its use is limited to research applications.
|
| ADME/Pharmacokinetics |
Helioxanthin has a molecular weight of 348.31 g/mol and a molecular formula of C20H12O6. It is a solid compound. For storage, it is recommended to keep the powder at -20°C for up to 3 years or at 4°C for up to 2 years. The compound is soluble in DMSO and other organic solvents. Detailed pharmacokinetic properties such as absorption, distribution, metabolism, and excretion (ADME) have not been extensively characterized. As a research compound, its stability under various conditions is primarily managed through proper storage as a dry powder.
|
| Toxicity/Toxicokinetics |
Detailed toxicity data for Helioxanthin is not provided in standard product descriptions. As a research compound with antiviral activity, its toxicity profile has not been extensively characterized. In vitro studies have not reported significant cytotoxicity at concentrations that are effective against HBV, but comprehensive toxicological studies are lacking. As with all research chemicals, standard laboratory safety precautions should be followed when handling Helioxanthin. Its use is limited to research applications and it is not intended for human or veterinary use.
|
| References |
|
| Additional Infomation |
Helioxanthin is a furan-naphthodioxane compound with the structure furano[3',4':6,7]naphtho[1,2-d][1,3]dioxanthin-7(9H)-one, where the 10-position is substituted with a 1,3-benzodioxanthin-5-yl group. It can inhibit the activity of hepatitis B virus (HBV), hepatitis C virus (HCV), and herpes simplex virus type 1 (HSV-1). Helioxanthin can be used as an anti-hepatitis B virus drug, a plant metabolite, and an antitumor drug. It belongs to the benzodioxanthin, furan-naphthodioxanthin, and lignan classes of compounds. It has been reported that helioxanthin exists in Hypoestes purpurea, Phoebe formosana, and other organisms with relevant data.
Helioxanthin (ACH126447) is a research compound and is not approved for any clinical or therapeutic use. It is a natural product with significant in vitro antiviral activity against hepatitis B virus (HBV), with an EC50 of 1 μM, and is also active against flaviviruses. It is used as a research tool to study the replication of HBV and flaviviruses and to explore potential antiviral strategies. Its mechanism of action is not fully elucidated, but it inhibits viral replication. Helioxanthin and its analogues represent a class of compounds with potential for development as antiviral agents. However, it is not a drug and has not undergone clinical trials. |
| Molecular Formula |
C20H12O6
|
|---|---|
| Molecular Weight |
348.31
|
| Exact Mass |
348.063
|
| CAS # |
18920-47-3
|
| Related CAS # |
Helioxanthin derivative 5-4-2;203935-39-1;Helioxanthin 8-1;840529-13-7
|
| PubChem CID |
177023
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
622.5±55.0 °C at 760 mmHg
|
| Flash Point |
277.1±31.5 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.723
|
| LogP |
3.7
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
26
|
| Complexity |
581
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
JUBRYHUFFFYTGR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H12O6/c21-20-12-5-10-2-4-15-19(26-9-24-15)18(10)17(13(12)7-22-20)11-1-3-14-16(6-11)25-8-23-14/h1-6H,7-9H2
|
| Chemical Name |
10-(1,3-benzodioxol-5-yl)-9H-[2]benzofuro[6,5-g][1,3]benzodioxol-7-one
|
| Synonyms |
HE-145 HE145. Helioxanthin HE 145
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8710 mL | 14.3550 mL | 28.7101 mL | |
| 5 mM | 0.5742 mL | 2.8710 mL | 5.7420 mL | |
| 10 mM | 0.2871 mL | 1.4355 mL | 2.8710 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
